Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2
Washington University in St. Louis · Harvard University · +4 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
481
total citations
- FWCI
- 9.99
- Percentile
- 100%
- References
- 94
Citations per year
Authors
25Topics & keywords
Topics
Keywords
- Biology
- Virology
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Antibody
- Coronavirus disease 2019 (COVID-19)
- 2019-20 coronavirus outbreak
- Viral replication
- Replication (statistics)
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- ELEli Lilly and Company
- HHHelen Hay Whitney FoundationAward: MA104
- WUWashington University in St. Louis
- VBVir Biotechnology
- NINational Institutes of HealthAwards: R37 AI059371, U01 AI151810, 75N93019C00062, HHSN272201700060C, R01 AI127828
- DADefense Advanced Research Projects AgencyAward: HR001117S0019
- WUWashington University School of Medicine in St. Louis